Guilin Huaxin Pharmacy Co. Ltd.

Primary Objective: This study used esomeprazole magnesium enteric-coated capsules (40 mg) produced and owned by Guilin Huaxin Pharmaceutical Co., Ltd. as the test formulation. In accordance with relevant bioequivalence regulations, esomeprazole magnesium enteric-coated capsules (40 mg, trade name: NEXIUM®) produced by AstraZeneca AB served as the reference formulation. The bioequivalence of the test and reference formulations was evaluated after administration in the fasting, fasting applesauce, and fed states. Secondary Objective: To observe the safety of the test and reference formulations, esomeprazole magnesium enteric-coated capsules, and esomeprazole magnesium enteric-coated capsules (NEXIUM®), in healthy volunteers.

The pharmacokinetic characteristics of ursodeoxycholic acid oral suspension (test preparation T, strength: 250mL: 12.5g, calculated as C24H40O4) provided by Guilin Huaxin Pharmaceutical Co., Ltd. and ursodeoxycholic acid oral suspension (reference preparation R, trade name: Ursofalk®, strength: 250mL: 12.5g, calculated as C24H40O4) certified by Dr. Falk Pharma GmbH were investigated in healthy subjects under fasting and postprandial conditions. The bioequivalence and safety of the two preparations were evaluated to provide a basis for the registration application of the test preparation.

Primary Objective: To compare the extent and rate of absorption of fexofenadine hydrochloride oral suspension (120 mL, 0.72 g) supplied by Guilin Huaxin Pharmaceutical Co., Ltd. and fexofenadine hydrochloride oral suspension (trade name: Children's Allegra Allergy®; strength: 30 mg/5 mL) licensed by Sanofi Aventis U.S. LLC in healthy Chinese subjects, under fasting and fed conditions. Secondary Objective: To evaluate the safety of fexofenadine hydrochloride oral suspension (120 mL, 0.72 g) supplied by Guilin Huaxin Pharmaceutical Co., Ltd. and fexofenadine hydrochloride oral suspension (trade name: Children's Allegra Allergy®; strength: 30 mg/5 mL) licensed by Sanofi Aventis U.S. LLC in healthy Chinese subjects, under fasting and fed conditions. To evaluate the palatability of fexofenadine hydrochloride oral suspension in healthy Chinese subjects and provide a basis for the taste of fexofenadine hydrochloride oral suspension.